ACADIA PHARMACEUTICALS INC. Deferred Income Tax Liabilities, Net
ACADIA PHARMACEUTICALS INC. (ACAD) had Deferred Income Tax Liabilities, Net of $11.16 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-02-26
- 2025-12-31: Deferred Income Tax Liabilities, Net $11.16M.
- 2024-12-31: Deferred Income Tax Liabilities, Net $11.42M.
- 2023-12-31: Deferred Income Tax Liabilities, Net $12.39M.
- 2022-12-31: Deferred Income Tax Liabilities, Net $13.23M.
| Period end | Deferred Income Tax Liabilities, Net | Deferred Income Tax Liabilities, Net as first filed |
|---|---|---|
| 2025-12-31 | $11.16M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $11.42M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $12.39M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $13.23M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $14.06M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $12.52M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $2.51M 10-K · filed 2021-02-25 | $2.30M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |